HRP20140326T1 - Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat - Google Patents
Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat Download PDFInfo
- Publication number
- HRP20140326T1 HRP20140326T1 HRP20140326AT HRP20140326T HRP20140326T1 HR P20140326 T1 HRP20140326 T1 HR P20140326T1 HR P20140326A T HRP20140326A T HR P20140326AT HR P20140326 T HRP20140326 T HR P20140326T HR P20140326 T1 HRP20140326 T1 HR P20140326T1
- Authority
- HR
- Croatia
- Prior art keywords
- chain
- benzylpiperidin
- group containing
- branched
- carbon atoms
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- UFFJZHVXSNLCEE-UHFFFAOYSA-N 2-(5-amino-4,6-dimethylpyrimidin-2-yl)oxy-n-(1-benzylpiperidin-4-yl)-n-methylacetamide Chemical compound N=1C(C)=C(N)C(C)=NC=1OCC(=O)N(C)C(CC1)CCN1CC1=CC=CC=C1 UFFJZHVXSNLCEE-UHFFFAOYSA-N 0.000 claims 2
- AIBXYKLRJAAKJA-UHFFFAOYSA-N 2-[(5-amino-4,6-dimethylpyrimidin-2-yl)amino]-n-(1-benzylpiperidin-4-yl)-n-methylacetamide Chemical compound N=1C(C)=C(N)C(C)=NC=1NCC(=O)N(C)C(CC1)CCN1CC1=CC=CC=C1 AIBXYKLRJAAKJA-UHFFFAOYSA-N 0.000 claims 2
- 206010019196 Head injury Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000028600 axonogenesis Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- UMOIRMMEJSLWBO-UHFFFAOYSA-N 2-(5-amino-4,6-dimethylpyrimidin-2-yl)oxy-n-(1-benzylpiperidin-4-yl)-n-cyclopropylacetamide Chemical compound CC1=C(N)C(C)=NC(OCC(=O)N(C2CC2)C2CCN(CC=3C=CC=CC=3)CC2)=N1 UMOIRMMEJSLWBO-UHFFFAOYSA-N 0.000 claims 1
- JQALKJZESFIISS-UHFFFAOYSA-N 2-(5-amino-4,6-dimethylpyrimidin-2-yl)oxy-n-(1-benzylpiperidin-4-yl)-n-methylpropanamide Chemical compound C1CN(CC=2C=CC=CC=2)CCC1N(C)C(=O)C(C)OC1=NC(C)=C(N)C(C)=N1 JQALKJZESFIISS-UHFFFAOYSA-N 0.000 claims 1
- ZEZQSXJOZPOWOG-UHFFFAOYSA-N 2-[5-amino-4,6-di(propan-2-yl)pyrimidin-2-yl]oxy-n-(1-benzylpiperidin-4-yl)-n-methylacetamide Chemical compound CC(C)C1=C(N)C(C(C)C)=NC(OCC(=O)N(C)C2CCN(CC=3C=CC=CC=3)CC2)=N1 ZEZQSXJOZPOWOG-UHFFFAOYSA-N 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- FBSZSNMZMHKNKB-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-2-[4,6-dimethyl-5-(methylamino)pyrimidin-2-yl]oxy-n-methylpropanamide Chemical compound N1=C(C)C(NC)=C(C)N=C1OC(C)C(=O)N(C)C1CCN(CC=2C=CC=CC=2)CC1 FBSZSNMZMHKNKB-UHFFFAOYSA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (7)
1. Spoj prikazan sa slijedećom formulom (I-aa):
[image]
naznačen time da
R1 i R2 su svaki neovisno atom vodika, atom halogena, hidroksil skupina, ravnolančana ili razgranata alkoksi skupina koja sadrži 1 do 5 ugljikovih atoma, acetil skupina, karbamoil skupina, karboksil skupina, ravnolančana ili razgranata ester skupina koja sadrži 1 do 5 ugljikovih atoma, nesupstituirana ili halogen-supstituirana ravnolančana, razgranata ili ciklička alkil skupina koja sadrži 1 do 5 ugljikovih atoma, ili -NR3R4 skupina pri čemu R3 i R4 su svaki neovisno atom vodika, atom kisika, nesupstituirana ili halogen-supstituirana ravnolančana, razgranata ili ciklička alkil skupina koja sadrži 1 do 5 ugljikovih atoma, ili ravnolančana ili razgranata alkiloksikarbonil skupina koja sadrži 2 do 10 ugljikovih atoma;
R5 i R6 su svaki neovisno atom vodika, ili nesupstituirana ili halogen-supstituirana ravnolančana, razgranata ili ciklička alkil skupina koja sadrži 1 do 5 ugljikovih atoma;
R7 je ravnolančana, razgranata ili ciklička alkil skupina koja sadrži 1 do 5 ugljikovih atoma;
E je atom kisika ili -NR8 skupina pri čemu R8 je atom vodika, ili ravnolančana ili razgranata alkil skupina koja sadrži 1 do 5 ugljikovih atoma;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da u formuli (I-aa), R1 i R2 su svaki metil skupina, R3, R4, R5, i R6 su svaki atom vodika, i R7 je C1 do C5 alkil skupina.
3. Spoj prema zahtjevu 1 naznačen time da je odabran je skupine koja sadrži:
N-(1-benzilpiperidin-4-il)-2-(4,6-dimetil-5-niropirimidin-2-ilamino) -N-metilacetamid;
2-(5-amino-4,6-dimetilpirimidin-2-ilamino)-N-(1-benzilpiperidin-4-il) -N-metilacetamid;
2-(5-amino-4,6-dimetilpirimidin-2-iloksi)-N-(1-benzilpiperidin-4-il)-N -metilacetamid;
2-(5-amino-4,6-dimetilpirimidin-2-iloksi)-N-(1-benzilpiperidin-4-il)-N -metilpropanamid;
N-(1-benzilpiperidin-4-il)-2-(4,6-dimetil-5-(metilamino)pirimidin-2-iloksi)-N-metilpropanamid;
2-(5-amino-4,6-dimetilpirimidin-2-iloksi)-N-(1-benzilpiperidin-4-il)-N -ciklopropilacetamid; i
2-(5-amino-4,6-diisopropilpirimidin-2-iloksi)-N-(1-benzilpiperidin-4-il )-N-metilacetamid;
ili njihova farmaceutski prihvatljiva sol.
4. Spoj prema zahtjevu 3, naznačen time da je odabran je skupine koja sadrži:
2-(5-amino-4,6-dimetilpirimidin-2-ilamino)-N-(1-benzilpiperidin-4-il) -N-metilacetamid; i
2-(5-amino-4,6-dimetilpirimidin-2-iloksi)-N-(1-benzilpiperidin-4-il)-N -metilacetamid;
ili njihova farmaceutski prihvatljiva sol.
5. Farmaceutski pripravak, naznačen time da kao aktivni sastojak sadrži spoj prema bilo kojem zahtjevu od 1 do 4, ili njegovu farmaceutski prihvatljivu sol.
6. Farmaceutski pripravak kako je definiran u zahtjevu 5 naznačen time da je za upotrebu za liječenje ili smanjenje bolesti, uključujući ozljede središnjeg živčanog sustava, kao što su trauma glave i ozljeda leđne moždine, moždani infarkt, ishemijske bolesti srca i bolesti začepljenja perifernih arterija, ili posljedica navedenih bolesti.
7. Sredstvo za poticanje aksonskog izrastanja i/ili poticanje angiogeneze ili terapeutsko sredstvo za liječenje ili smanjenje bolesti uključujući ozljede središnjeg živčanog sustava, kao što su trauma glave i ozljeda leđne moždine, moždani infarkt, ishemijske bolesti srca i bolesti začepljenja perifernih arterija, ili posljedica navedenih bolesti, pomoću poticanja aksonskog izrastanja i/ili poticanja angiogeneze, naznačen time da kao aktivni sastojak sadrži spoj prema zahtjevima 1 do 4, ili njegovu farmaceutski prihvatljivu sol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007118768 | 2007-04-27 | ||
| PCT/JP2008/058081 WO2008139894A1 (ja) | 2007-04-27 | 2008-04-25 | 含窒素芳香族６員環誘導体並びにそれらを含む医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140326T1 true HRP20140326T1 (hr) | 2014-05-09 |
Family
ID=40002110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140326AT HRP20140326T1 (hr) | 2007-04-27 | 2014-04-04 | Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8592435B2 (hr) |
| EP (2) | EP2151439B1 (hr) |
| JP (1) | JP5197584B2 (hr) |
| KR (1) | KR101456316B1 (hr) |
| CN (2) | CN101730691A (hr) |
| AU (1) | AU2008249329C1 (hr) |
| BR (1) | BRPI0810821A8 (hr) |
| CA (1) | CA2683941C (hr) |
| CY (1) | CY1115377T1 (hr) |
| DK (1) | DK2151439T3 (hr) |
| ES (2) | ES2453590T3 (hr) |
| HR (1) | HRP20140326T1 (hr) |
| MX (1) | MX2009011369A (hr) |
| PL (1) | PL2151439T3 (hr) |
| PT (1) | PT2151439E (hr) |
| RU (1) | RU2470927C2 (hr) |
| SI (1) | SI2151439T1 (hr) |
| WO (1) | WO2008139894A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012002807B1 (pt) * | 2009-08-07 | 2018-07-10 | Adama Makhteshim Ltd. | Derivados de 5-flúor-2-oxopirimidina-1(2h)- caboxilato, composição e processo para controle e prevenção de ataque fúngico em uma planta de ataque fúngico em uma planta |
| UA112284C2 (uk) * | 2009-08-07 | 2016-08-25 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Похідні 5-фторпіримідинону |
| UA115462C2 (uk) | 2012-12-28 | 2017-11-10 | Адама Махтешім Лтд. | Похідні n-(заміщеного)-5-фтор-4-іміно-3-метил-2-оксо-3,4-дигідропіримідин-1(2h)-карбоксилату |
| UA117743C2 (uk) | 2012-12-28 | 2018-09-25 | Адама Махтешім Лтд. | N-(заміщені)-5-фтор-4-іміно-3-метил-2-оксо-3,4-дигідропіримідин-1(2h)-карбоксамідні похідні |
| MX2015008565A (es) | 2012-12-31 | 2015-09-07 | Dow Agrosciences Llc | Derivados de 3-alquil-5-fluoro-4-sustituido-imino-3,4-dihidropirim idin-2(1h)-ona como fungicidas. |
| WO2016047662A1 (ja) * | 2014-09-25 | 2016-03-31 | 第一三共株式会社 | 脳卒中の治療剤 |
| WO2016086105A1 (en) * | 2014-11-25 | 2016-06-02 | Shriners Hospitals For Children | MODEL SYSTEMS FOR SCREENING MODULATORS OF mTOR SIGNALING |
| CN114570418B (zh) * | 2022-02-22 | 2023-10-17 | 陕西延长石油（集团）有限责任公司 | 一种羟基乙酸甲酯制备肌氨酸甲酯及肌氨酸的催化剂及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1260474A (en) | 1984-12-03 | 1989-09-26 | Raymond A. Stokbroekx | Benzoxazol- and benzothiazolamine derivatives |
| GB8912700D0 (en) * | 1989-06-02 | 1989-07-19 | Shell Int Research | Herbicidal compounds |
| DE68914197T2 (de) * | 1988-06-20 | 1994-11-10 | Ihara Chemical Ind Co | Alkansäurederivate und herbizide Mittel. |
| JP2771604B2 (ja) * | 1988-06-20 | 1998-07-02 | クミアイ化学工業株式会社 | 除草剤及びその有効成分となる新規なアルカン酸誘導体 |
| GB8917476D0 (en) * | 1989-07-31 | 1989-09-13 | Shell Int Research | Sulphonamide herbicides |
| JP2002527477A (ja) | 1998-10-16 | 2002-08-27 | サントリー株式会社 | 神経細胞保護作用物質としてのアミノフェノキシ酢酸誘導体 |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| CN1264821C (zh) * | 2000-04-13 | 2006-07-19 | 第一阿斯比奥制药株式会社 | 氨基苯氧基乙酰胺衍生物和含有它们的药物组合物 |
| US7115635B2 (en) | 2001-04-27 | 2006-10-03 | Mitsubishi Pharma Corporation | Benzylpiperidine compound |
| US7205307B2 (en) * | 2002-02-14 | 2007-04-17 | Icagen, Inc. | Pyrimidines as novel openers of potassium ion channels |
| CA2490397A1 (en) * | 2002-06-24 | 2003-12-31 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| MY142362A (en) * | 2004-01-29 | 2010-11-30 | Otsuka Pharma Co Ltd | Pharmaceutical composition for promoting angiogenesis |
| JP4916115B2 (ja) | 2004-01-29 | 2012-04-11 | 大塚製薬株式会社 | 血管新生促進剤 |
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| US20090197914A1 (en) | 2006-03-07 | 2009-08-06 | Peter Cage | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them |
-
2008
- 2008-04-25 BR BRPI0810821A patent/BRPI0810821A8/pt not_active Application Discontinuation
- 2008-04-25 AU AU2008249329A patent/AU2008249329C1/en not_active Ceased
- 2008-04-25 RU RU2009143850/04A patent/RU2470927C2/ru not_active IP Right Cessation
- 2008-04-25 JP JP2009514083A patent/JP5197584B2/ja not_active Expired - Fee Related
- 2008-04-25 CA CA 2683941 patent/CA2683941C/en not_active Expired - Fee Related
- 2008-04-25 DK DK08764246T patent/DK2151439T3/en active
- 2008-04-25 CN CN200880021294A patent/CN101730691A/zh active Pending
- 2008-04-25 KR KR1020097024649A patent/KR101456316B1/ko active IP Right Grant
- 2008-04-25 SI SI200831176T patent/SI2151439T1/sl unknown
- 2008-04-25 PL PL08764246T patent/PL2151439T3/pl unknown
- 2008-04-25 WO PCT/JP2008/058081 patent/WO2008139894A1/ja active Application Filing
- 2008-04-25 EP EP20080764246 patent/EP2151439B1/en active Active
- 2008-04-25 CN CN201310302307.2A patent/CN103396399B/zh not_active Expired - Fee Related
- 2008-04-25 MX MX2009011369A patent/MX2009011369A/es active IP Right Grant
- 2008-04-25 PT PT87642468T patent/PT2151439E/pt unknown
- 2008-04-25 EP EP13185144.6A patent/EP2679586B1/en not_active Not-in-force
- 2008-04-25 US US12/596,054 patent/US8592435B2/en not_active Expired - Fee Related
- 2008-04-25 ES ES08764246T patent/ES2453590T3/es active Active
- 2008-04-25 ES ES13185144.6T patent/ES2566327T3/es active Active
-
2012
- 2012-05-29 US US13/482,375 patent/US8685989B2/en not_active Expired - Fee Related
-
2014
- 2014-02-05 US US14/173,327 patent/US9139559B2/en not_active Expired - Fee Related
- 2014-04-04 HR HRP20140326AT patent/HRP20140326T1/hr unknown
- 2014-05-26 CY CY20141100376T patent/CY1115377T1/el unknown
- 2014-07-22 US US14/337,586 patent/US9156817B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140326T1 (hr) | Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat | |
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| ES2683355T3 (es) | Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades | |
| HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| JP2014507455A5 (hr) | ||
| JP2014506907A5 (hr) | ||
| JP2009504763A5 (hr) | ||
| JP2019517487A5 (hr) | ||
| JP2017531020A5 (hr) | ||
| JP2017533968A5 (hr) | ||
| JP2018505898A5 (hr) | ||
| JP2008509187A5 (hr) | ||
| JP2014511892A5 (hr) | ||
| MX2012009079A (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| JP2009504764A5 (hr) | ||
| JP2015514135A5 (hr) | ||
| MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| WO2006122011A3 (en) | Thiazole compounds and methods of use | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| WO2005067900A3 (en) | Azabenzofuran substituted thioureas as inhibitors of viral replication | |
| RU2004100302A (ru) | Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащие их фармацевтические композиции | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| WO2005095345A3 (en) | Heteroaryl guanidines as inhibitors of viral replication | |
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora |